Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F3 | P13726 | 1/20 | 0.59 |
| ▸ | CES2 | O00748 | 1/20 | 0.59 |
| ▸ | CES1 | P23141 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 4/20 | 0.57 |
| ▸ | CA2 | P00918 | 4/20 | 0.57 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.57 |
| ▸ | ABAT | P80404 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | PARP1 | P09874 | 1/20 | 0.55 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.55 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.55 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.55 |
| ▸ | TGM2 | P21980 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenol SCHEMBL14911004 | 0.88 | ALDH5A1 (0.59) | F3CES2CES1MAPTALDH1A1 | |
| SCHEMBL7000262 | 0.83 | F3 (0.75) | F3CES2CES1MAPTALDH1A1 | |
| SCHEMBL7000261 | 0.83 | F3 (0.75) | F3CES2CES1MAPTALDH1A1 | |
| SCHEMBL4256312 | 0.82 | ALDH5A1 (0.80) | F3MAPTALDH1A1HPGDALDH5A1 | |
| SCHEMBL6260774 | 0.81 | F3 (0.62) | F3CES2CES1MAPTALDH1A1 | |
| SCHEMBL1641142 | 0.81 | CES2 (0.61) | F3CES2CES1MAPTALDH1A1 | |
| SCHEMBL28111426 | 0.81 | CES2 (0.61) | F3CES2CES1MAPTALDH1A1 | |
| SCHEMBL31119870 | 0.80 | HDAC3 (0.61) | CES2CES1MAPTALDH1A1CA1 | |
| SCHEMBL14903558 | 0.80 | ELANE (0.56) | MAPTALDH1A1HPGDALDH5A1ABAT | |
| SCHEMBL19309804 | 0.79 | F3 (0.59) | F3CES2CES1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111116693-B | Method for preparing sofosbuvir by combining 3, 3-diaryl acrolein and Grignard reagent | 江苏科本药业有限公司 | 2021-04-27 | — | — | CN | claimed |
| CN-111233645-A | Method for preparing tri-substituted cyclopentene by MBH/Wittig domino reaction of vinylon insertion | 浙江大学 | 2020-06-05 | — | — | CN | claimed |
| CN-111116693-A | Method for preparing sofosbuvir by combining 3, 3-diaryl acrolein and Grignard reagent | 江苏科本药业有限公司 | 2020-05-08 | — | — | CN | claimed |
| WO-2015015511-A1 | NOVEL METAL FREE PROCESS FOR ALLYLIC OXIDATION | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-02-05 | — | — | WO | claimed |
| US-7875285-B1 | n acrylic ester polymer including a drug having anovercoating of a different acrylic ester polymer having a glass transition temperature of 35-50 degrees C. to control elution of the drug; temperature change morphology of drug polymer to change and increase release; thrombolytic agents; restenosis | ADVANCED CARDIOVASCULAR SYSTEMS, INC. (US) | 2011-01-25 | — | — | US | claimed |
| US-7105274-B2 | Photoluminescent ethylene sensors | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2006-09-12 | — | — | US | claimed |
| US-20250376441-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | UNIV YONSEI IACF (KR) | 2025-12-11 | — | — | US | disclosed |
| EP-3656756-B1 | PROCESS FOR THE DIRECT ALPHA-METHYLENATION OF KETONES | SPECIALTY OPERATIONS FRANCE (FR) | 2025-12-03 | — | — | EP | disclosed |
| CN-116143718-B | Anti-hepatitis B activity (E) - (3-phenyl isoxazole-5-) -methylene acetophenone oxime ether derivatives | 广西大学 | 2024-12-06 | — | — | CN | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| CN-113166027-B | Direct alpha-methylation of ketones | 罗地亚经营管理公司 | 2024-10-25 | — | — | CN | disclosed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| CN-112004805-B | Process for producing 5, 5-disubstituted-4, 5-dihydroisoxazoles | 组合化学工业株式会社 | 2024-06-14 | — | — | CN | disclosed |
| WO-1997049736-A2 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. SEARLE AND CO. (US) | 1997-12-31 | — | — | WO | disclosed |
| EP-0543861-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1993-06-02 | — | — | EP | disclosed |
| WO-1992003422-A1 | BENZIMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1992-03-05 | — | — | WO | disclosed |
| EP-0073456-B1 | TETRAAZAANNULENE COBALT COMPLEX COMPOUNDS AND METHOD FOR PREPARATION THEREOF | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1985-11-27 | — | — | EP | disclosed |
| EP-0004624-B1 | CHROMANON DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICINES AND GROWTH-PROMOTING AGENTS | BAYER AG (DE) | 1982-02-24 | — | — | EP | disclosed |
| US-4261988-A | ANTICHOLESTEROL AGENTS USED IN ANIMAL HUSBANDRY | BAYER AKTIENGESELLSCHAFT (DE) | 1981-04-14 | — | — | US | disclosed |
| EP-0004624-A2 | Chromanon derivatives, process for their preparation, and their use as medicines and growth-promoting agents | BAYER AG (DE) | 1979-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250376441-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | PRKAA1, PRKAA2, PRKAG1 | F3 3918/4885CES2 2668/4885CES1 2355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.